Antibiotic Discovery and Development
Thomas J. Dougherty, Michael J. Pucci
Springer Science & Business Media, Dec 18, 2011 - Medical - 1127 pages
This volume covers all aspects of the antibiotic discovery and development process through Phase II/III. The contributors, a group of highly experienced individuals in both academics and industry, include chapters on the need for new antibiotic compounds, strategies for screening for new antibiotics, sources of novel synthetic and natural antibiotics, discovery phases of lead development and optimization, and candidate compound nominations into development. Beyond discovery , the handbook will cover all of the studies to prepare for IND submission: Phase I (safety and dose ranging), progression to Phase II (efficacy), and Phase III (capturing desired initial indications). This book walks the reader through all aspects of the process, which has never been done before in a single reference. With the rise of antibiotic resistance and the increasing view that a crisis may be looming in infectious diseases, there are strong signs of renewed emphasis in antibiotic research. The purpose of the handbook is to offer a detailed overview of all aspects of the problem posed by antibiotic discovery and development.
What people are saying - Write a review
We haven't found any reviews in the usual places.
Part II Marketed Major Classes of Compounds
Part III The Rise of Antibiotic ResistanceResistance Mechanisms to Major Classes
Part IV Clinical Issues of Resistance Worst Offenders List of Problematic Microbes
Part VI Mycobacteria
Part VII Antibiotic Discovery
Other editions - View all
aminoglycosides antibacterial activity antibacterial agents antibiotic resistance Antimicrob Agents Chemother Antimicrob Chemother azithromycin b-lactam antibiotics b-lactamase Bacteriol beta-lactamase binding Biol carbapenems cell wall cephalosporins cethromycin Chem chromosome ciprofloxacin clarithromycin Clin Infect Clin Microbiol clinical isolates clones compounds concentration dalbavancin discovery dose drug efflux pump efflux system encoding Enterobacteriaceae enterococci enzymes erythromycin ESBLs Escherichia coli faecalis faecium fluoroquinolones genetic genome gentamicin glycopeptide Gram-negative Gram-negative bacteria Gram-positive gyrase identified induced inhibition inhibitors ketolides linezolid macrolides mechanism methicillin-resistant mg/mL molecular molecules MRSA multidrug efflux multidrug resistance mutations Mycobacterium natural products novel oral organisms oritavancin outer membrane oxazolidinone pathogens patients PBP2x PBPs penicillin peptide peptidoglycan permeability pharmacokinetic phenotype plasmid Pseudomonas aeruginosa quinolone resistance genes ribosome screening sequence specific Staphylococcus aureus strains Streptococcus pneumoniae structure studies susceptibility synthesis target teicoplanin telavancin telithromycin tet genes tetracycline therapy tigecycline tion transposon treatment tuberculosis vancomycin vancomycin-resistant vitro activity vivo